Nanthealth — Investor Presentation (August 2016)
15 slides from Nanthealth's investor presentation, Aug 10, 2016
Slide 1: NantHealth Investor Presentation
NantHealth Investor Presentation Next-generation, evidence-based, personalized healthcare company August 2016 NASDAQ: NH Robert Watson, President Exhibit 99.1
Slide 2: Disclosure Statements
Disclosure Statements This presentation has been prepared by NantHealth, Inc. (the “Company”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or the Compa
Slide 3: About NantHealth
About NantHealth Founded by Dr. Patrick Soon-Shiong in 2010 IPO in June 2016 (NASDAQ: NH) 850+ associates worldwide Headquarters: Culver City, CA Worldwide offices: Boston (MA), Dallas (TX), Philadelphia (PA), Cleveland (OH), Panama City (FL), Melbourne (FL), Phoenix (AZ), Hyderabad (India), London
Slide 4: Multi-Billion Dollar, Rapidly Growing Market Opportunity
Multi-Billion Dollar, Rapidly Growing Market Opportunity Transition to Patient Centric, Value-Based Care $765bn of waste in the US Increased prevalence of value-based models such as ACOs Lack of coordination / interoperability amongst silos of care $250bn precision medicine market Evolution toward c
Slide 5: Vision Toward Integrated Learning System for Healthcare
Vision Toward Integrated Learning System for Healthcare NantHealth - Confidential, Do Not Distribute PAYOR DOMAIN KNOWLEDGE DOMAIN DELIVERY DOMAIN Better Outcomes & Lower Cost Right Diagnosis Right Decision Right Rx Right Place Right Time Right Caregiver Care Coordination Connecting Academic Centers
Slide 6: Comprehensive Solutions for Providers, Payors & Employers
Comprehensive Solutions for Providers, Payors & Employers G P S Genomic Proteomic Spectrometry GPS CancerTM NantHealth Technology Solutions Oncology decision support (eviti) Clinical learning and analytics Provider portal Patient portal Care coordination Payer-provider collaboration (NaviNet Open) D
Slide 7: GPS Guided Cancer Treatment
GPS Guided Breast Cancer Treatment Oxaliplatin ERCC1 TOPO1 Irinotecan EGFR Cetuximab, Panitumumab TUBβ3 Docetaxel FRα Pemetrexed Nivolumab PD-L1 ALK hENT1 Gemcitabine Crizotinib hENT1 Gemcitabine TOPO2A Doxorubicin Paclitaxel TUBβ3 HER2 Trastuzumab, Pertuzumab … GPS Guided Colon Cancer Treatment GPS
Slide 8: Our Global Scale
Our Global Scale >100,000,000 Covered lives on our Provider and Payor Platforms ~30,000,000 Payor-provider transactions monthly Of U.S. oncology practices have used our decision support platform Of vital signs captured annually Unique in hospital medical devices integrated Of U.S. physicians’ office
Slide 9: Leading Payor Clients Nationwide
Leading Payor Clients Nationwide
Slide 10: Leading Health System Clients Worldwide
Leading Health System Clients Worldwide United States Advocate Allina Central Maine Cleveland Clinic Cooks Children’s Dallas Children’s Franciscan Ministries Kaiser Permanente Northwestern Presence Health Phoebe Putney Canada cGTA (Connecting Greater Toronto Area) UHN United Kingdom Derby East Kent
Slide 11: Experienced Management Team
Experienced Management Team Sarah Chavarria Chief People Officer Chuck Digate SVP, Marketing & Business Development Gary Palmer President, GPS Operations Bob Watson President and Chief Growth Officer Mark Dudman President, Product Operations Charles Kim General Counsel Paul Holt Chief Financial Offi
Slide 12: Q2 2016 Business Highlights
Q2 2016 Business Highlights IPO on June 2, 2016 (NASDAQ: NH) Commercial availability of GPS Cancer, leading comprehensive molecular test integrating quantitative proteomics and genomics Growing adoption from physicians nationwide and internationally 180,000 patients with cancer covered by a payer fo
Slide 13: Q2 2016 Financial Highlights
Q2 2016 Financial Highlights Three months ended June 30, 2016 Net revenue = $31.5 million Up from $11.8 million in Q2 2015; 167% growth Gross profit = $9.3 million Up from $5.5 million in Q2 2015; 69% growth Net profit = ($54.1 million) Total bookings = $12.0 million EPS (GAAP) = ($0.52) EPS (non-GA
Slide 14: Company Summary
Company Summary Exchange / Ticker NASDAQ: NH Share Price (52-week range) August 1, 2016: $9.98 (52-week high – $21.00; low - $9.79) Common shares outstanding 120.7 million Market cap $1.2 billion Cash $95.2 million (June 30, 2016) Bank debt $112.7 million (June 30, 2016) Net revenue Q2 2016: $31.5 m
Slide 15: Thank You
Thank You